Skip to main content

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces August 2020 as the Best Revenue Month in Company History

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, CA, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® Brasil had its best revenue month ever in Company history in August 2020.
“Since 2015, HempMeds® Brasil has sold more than 80,000 units of cannabidiol (CBD) to Brazilian citizens,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are proud to be the recipients of the first permits to import CBD into Brazil and we have been able to become industry leaders there.”“Our Company was formed and is led by Brazilians – we care immensely about providing people here with affordable, high-quality CBD products that are legal and scientifically-proven,” said HempMeds® Co-CEO Caroline Heinz. “We have showcased to citizens even despite a global pandemic and a very poor currency exchange rate, we have been able to increase our sales and make our products affordable for the struggling economy through adjusting our prices and offering payment plans.”Before becoming Co-CEO of HempMeds®’ operations, Heinz served as Vice President of HempMeds® Brasil. She joined the Company in 2014 and helped pass legislation to get the Brazilian government to subsidize CBD for several indications. She was also able to establish two HempMeds® Brasil offices and create a network of Brazilian doctors and medical professionals.To learn more about HempMeds® Brasil, please visit them online at https://hempmedsbr.com/ or on Instagram at https://www.instagram.com/hempmedsbrasil/.About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications. www.hempmeds.com.br.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT:Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.